Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
02 nov. 2023 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
30 août 2023 16h05 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 16h05 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
26 juin 2023 08h30 HE
|
Acer Therapeutics Inc.
Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer...
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
15 mai 2023 17h10 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
01 mai 2023 08h30 HE
|
Acer Therapeutics Inc.
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at...
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
27 mars 2023 16h01 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
22 mars 2023 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
22 mars 2023 08h00 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial
17 mars 2023 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...